title: [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].
abstract: BACKGROUND
  The medical use of cannabis is discussed in gastroenterology for inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and chronic pancreatitis.
  
  
  METHODS
  A systematic literature search until March 2015 was performed in the databases Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, www.cannabis-med.org , and clinicaltrials.gov. Randomized controlled trials (RCT) investigating herbal cannabis and/or pharmaceutical cannabinoids in IBD, IBS, or chronic pancreatitis with a study duration of ≥ 4 weeks and a sample size of at least n = 10 per study arm were identified. Clinical outcomes comprised efficacy (pain, nausea, appetite/weight, diarrhea, health-related quality of life, and remission rates for IBD), tolerability (drop-out rate due to side effects), and safety (severe side effects). Methodology quality of RCTs was evaluated with the Cochrane Risk of Bias Tool.
  
  
  RESULTS
  Only one RCT treating 21 patients with Crohn's disease and herbal cannabis was identified. The study revealed no significant differences of remission rate because of low statistical power. However, there was a clear tendency for less abdominal pain and improved appetite with medical cannabis. The methodological risk of the study was high. Furthermore, results of two RCTs investigating synthetic cannabis in IBD and chronic pancreatitis, respectively, have not yet been released. No RCT for IBS was found. Several case reports described cannabis-induced acute pancreatitis.
  
  
  CONCLUSIONS
  Cannabis may be useful for symptom relief in Crohn's disease such as pain, nausea, and loss of appetite. However, studies with high methodological quality, sufficient sample size, and study duration are mandatory to determine potential therapeutic effects and risks of cannabis in gastroenterology. Currently, use of tetrahydrocannabinol to alleviate symptoms such as pain and appetite loss in Crohn's disease should only be considered in individual patients after failure of established medical therapies and only after careful risk-benefit assessment.
authors.affiliation: Medizinische Klinik mit Schwerpunkten Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Deutschland.
authors.forename: M S
authors.initials: MS
authors.lastname: Volz
authors.affiliation: Medizinische Klinik mit Schwerpunkten Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Deutschland.
authors.forename: B
authors.initials: B
authors.lastname: Siegmund
authors.affiliation: Innere Medizin I, Klinikum Saarbrücken gGmbH, Winterberg 1, 66119, Saarbrücken, Deutschland. whaeuser@klinikum-saarbruecken.de.|Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Technische Universität München, München, Deutschland. whaeuser@klinikum-saarbruecken.de.
authors.forename: W
authors.initials: W
authors.lastname: Häuser
mesh_terms: D002186:Cannabinoids / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000000981:diagnostic imaging*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D064086:Medical Marijuana / Q000008:administration & dosage* / Q000627:therapeutic use*; D050500:Pancreatitis, Chronic / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D002186:Cannabinoids; D064086:Medical Marijuana
keywords: Cannabis; Inflammatory bowel disease; Irritable bowel syndrome; Pancreatitis, chronic; Randomized controlled trials
references.citation: Pain Med. 2009 Nov;10(8):1353-68
references.pmid: 19732371
references.citation: Inflamm Bowel Dis. 2013 Dec;19(13):2809-14
references.pmid: 24185313
references.citation: Inflamm Bowel Dis. 2014 Mar;20(3):472-80
references.pmid: 24407485
references.citation: World J Gastroenterol. 2014 Apr 7;20(13):3663-71
references.pmid: 24707152
references.citation: Schmerz. 2015 Feb;29(1):8-34
references.pmid: 25472889
references.citation: Expert Rev Clin Pharmacol. 2010 Mar;3(2):193-207
references.pmid: 22111567
references.citation: Pharmacol Ther. 2010 Apr;126(1):21-38
references.pmid: 20117132
references.citation: JOP. 2007 Sep 07;8(5):579-83
references.pmid: 17873462
references.citation: Nature. 2002 Aug 1;418(6897):530-4
references.pmid: 12152079
references.citation: Qual Life Res. 2014 Feb;23(1):1-4
references.pmid: 23722635
references.citation: J Physiol Pharmacol. 2013 Apr;64(2):167-75
references.pmid: 23756391
references.citation: Pain. 2013 Dec;154 Suppl 1:S87-93
references.pmid: 23623250
references.citation: Neurogastroenterol Motil. 2012 Apr;24(4):358-e169
references.pmid: 22288893
references.citation: Neuro Endocrinol Lett. 2014;35(3):198-201
references.pmid: 24977967
references.citation: Dtsch Arztebl Int. 2012 Jul;109(29-30):495-501
references.pmid: 23008748
references.citation: Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
references.pmid: 19622511
references.citation: Biochem Pharmacol. 2013 May 1;85(9):1306-16
references.pmid: 23415610
references.citation: Digestion. 2012;85(1):1-8
references.pmid: 22095142
references.citation: JAMA. 2003 Apr 16;289(15):1929-31
references.pmid: 12697794
references.citation: Presse Med. 2015 Apr;44(4 Pt 1):468-71
references.pmid: 25650297
references.citation: C R Acad Sci Hebd Seances Acad Sci D. 1973 Sep 17;277(11):979-80
references.pmid: 4276944
references.citation: Pancreas. 2010 Nov;39(8):1205-10
references.pmid: 20622705
references.citation: Neurogastroenterol Motil. 2011 Jan;23(1):30-5, e2
references.pmid: 20718944
references.citation: Dig Dis. 2014;32(4):468-74
references.pmid: 24969296
references.citation: BMJ. 2001 Jul 7;323(7303):13-6
references.pmid: 11440935
references.citation: Chem Phys Lipids. 2000 Nov;108(1-2):169-90
references.pmid: 11106790
references.citation: PLoS One. 2008 Feb 27;3(2):e1701
references.pmid: 18301776
references.citation: Isr Med Assoc J. 2011 Aug;13(8):455-8
references.pmid: 21910367
references.citation: Gastroenterology. 2011 Nov;141(5):1638-47.e1-7
references.pmid: 21803011
references.citation: Aliment Pharmacol Ther. 2005 Apr 15;21(8):921-31
references.pmid: 15813828